The 17th DIA China Annual Meeting 2025 was held from May 22 (Thu) to May 25 (Sun), 2025 at the Shanghai Zhangjiang Science Hall.

On May 24 (Sat) (Day 2), the session titled “The Japanese Market Demystified – A Prime Opportunity for Chinese Enterprises to Expand Globally” was held as the only Japan-China joint session at this year’s DIA China Annual Meeting.

This session was organized and operated by “Drug Research and Development (R&D) Expert” with support from DIA China, the China-Japan Medical and Material Technology Innovation Center (CJMMIC), and other organizations.

This was the second Japan-China session organized by “Drug R&D Expert” following the COVID-19 pandemic.  Like the previous session in 2023, it was chaired by Dr. Ling Su, a renowned DIA Fellow from China, and Dr. Akio Uemura, former DIA Japan SVP & Managing Director.  Keynote lectures were delivered by Prof. Yoshiaki Uyama, Associate Executive Director, PMDA and Prof. Kenichi Nakamura, National Cancer Center Hospital, Japan.  Following the keynote lectures, panel discussions were held where Dr. Jin Li (VP, Regulatory Affairs, Henlius Biotech), Dr. Yiming Du (SVP, Clinical Operations, Clinical Registration and Pharmacovigilance, Haihe Biopharma), Mr. Fei Liang (Chairperson, Chuangjian Pharmaceutical Development Shanghai), and Mr. Tetsuomi Takano (Editor-in-Chief, Drug R&D Expert) also participated.

Despite the simultaneous holding of 13 sessions, this session was so well-attended that standing room was required, with over 100 participants engaging in lively discussions.